Studien & Berichte

Il Dong Biosciences reported that its probiotic strain IDCC 1201 improved gut symptoms and quality of life in adults with functional bowel disorders, results published in Nutrients.

Il Dong BioScience announced that its probiotic strain IDCC 1201 reduced abdominal bloating and altered gut microbiota in a clinical trial, with results published in the journal Nutrients.

Phase 2 of BioNTech and Genentech's personalized mRNA colorectal cancer vaccine BNT122 was stopped early after higher deaths in the vaccine arm.

A UK randomized trial of 339 patients found robot-assisted knee arthroplasty improves surgical precision but offers no significant advantage in pain, function, or recovery after one year.

A ChAdOx1 BDBV vaccine targeting the Bundibugyo Ebola virus begins a Phase 1 safety and immunogenicity study in 50 healthy UK adults aged 18‑55.

The co‑developed oral GLP‑1/GLP‑2 dual‑action obesity candidate RPG‑102 showed higher drug exposure and comparable durability versus subcutaneous injection in early Phase 1a data.

STP0404, an HIV‑1 treatment candidate from ST Pharm, demonstrated significant antiviral effects across all dose groups in a US Phase 2a study, prompting optimism for further development.

Ipsen reported that its botulinum toxin Dysport achieved primary goals in two Phase 3 studies for preventing episodic and chronic migraine, marking the first positive result in episodic migraine for a botulinum product.

Satellos Bioscience observed a drug activity signal for its oral AAK1‑targeting candidate SAT‑3247 in a Phase 1a/b trial of four adult Duchenne muscular dystrophy patients.

Xiaflex, the injectable enzyme already approved for Dupuytren's contracture and Peyronie's disease, achieved the primary endpoint in a phase 3 study of 436 plantar fibromatosis patients, opening a potential third indication.

Hanmi Pharm is developing Belvarafenib, the first oral targeted therapy for NRAS‑mutant melanoma, now in Phase 2 with a goal of conditional approval by 2028.

Novartis Korea presented up to 6‑year follow‑up results and real‑world data for its PNH therapy iptacopan (PAVALTA) at the EHA 2026 meeting in Milan.